Prospective study to assess lung cancer screening with low dose CT scan (LDCT) in Latin America (LATAM) and prospectively evaluate chest-XRay analyzed with artificial intelligence (AI) using qXRin (QURE ai) at the initial visit correlating with the findins of the initial LDCT in patients with other high risk criteria to develop lung cancer. 2000 patients will be recruited in 4 LATAM countries (Mexico 700 pts, Costa Rica 300 pts, Colombia 500 pts, Argentina 500 pts). All patients will be ≥50years of age with one of the following additional inclusion criteria: a. exposure to wood smoke (at least 100 hours/year), b.family history of lung cancer in a first degree relative, c. COPD and/or emphysema, d. smokers with a tobacco index of 10 y or more. The exclusion criteria include: a. lung cancer diagnosis or other type of cancer 5 years prior to screening, b. loss of 10% of baseline weight 6 months before inclusion, c. ineligible for LDCT, d. life expectancy ≤5 years, and e. previous history of pulmonary nodules.
The primary objective of the study is the utility of LDCT-based lung cancer screening in identifying suspicious lung nodules in smokers and non-smokers across LATAM, with secondary objectives including: 1- Utility of qXR-LNMS (lung nodule malignancy score) of chest XRay for lung cancer risk assessment to exclude low risk patients from LDCT screening, 2- Utility of LDCT-based lung cancer screening in subjects with various risk profiles in LATAM, 3- Prevalence of lung nodules in the study population, 4-Mortality rate in the subjects diagnosed with an anomaly in the LDCT (with or without LC diagnosis).
Exposure to wood smoke (at least 100 hours per year)
A family history of lung cancer in first-degree relatives
A diagnosis of COPD and/or emphysema
Smokers with a tobacco index of 10 years or more
Lung cancer diagnosis or any other type of active cancer during the 5 years prior to the screening
Incomplete clinical information
Loss of 10% of the baseline weight during 6 months prior to study entry
Having a functional status, psychiatric condition or comorbidity that precludes curative treatment
2000 patients will be recruited in 4 Latin American countries (Mexico 700 pts,Costa Rica 300 pts, Colombia 500 pts, Argentina 500 pts)
Cohort
Prospective
Chest X-Ray, Low Dose CT scan
Diagnostic testVisit 1: chest XRay analyzed by qXR (QURE ai) and LDCT1 Visit 2: LDCT2 : (12/24 months as applicable ± 2 weeks)(interval of LDCT2 is determined by the findings of the Visit 1) 1. Low risk by qXR and Lung RADS 1 or 2: repeat in 24 months 2. Low risk by qXR and Lung RADS 3, high risk by qXR and Lung RADS 1, 2, 3: repeat in 12 months Telephonic follow-up visits (at 6 month interval post LDCT2 for 2 years) Any Lung RADS 0, 4A, 4B, 4X or S will be assed in a thoracic oncology multidisciplinary team
Utility of LDCT-based lung cancer screening in identifying suspicious lung nodules in smokers and non-smokers across LATAM
Utility of qXR-LNMS of CXR for lung cancer risk assessment to exclude low risk patients from LDCT screening
Utility of LDCT-based LC screening in subjects with various risk profiles in LATAM
Prevalence of lung nodules in the study population
Mortality rate in subjects diagnosed with an anomaly in the LDCT (with or without LC diagnosis)
Click on the lead sponsor to view all of their trials.
Latin American Consortium for the Lung Cancer Research
Lead sponsor
Centro de Investigacion y Manejo del Cancer (CIMCA)
Collaborator
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Collaborator
Instituto Nacional de Cancerologia de Mexico
Collaborator
Alexander Fleming Institute
Collaborator
This trial is not recruiting at the moment. You can still explore other options: